Pirtobrutinib Produces Durable Responses in Pretreated MCL
Nirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.
CAR T Cell Therapy Shows Efficacy in B Cell Malignancies in Phase 1 Trial
Nirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.